| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -706.22% | -187.18% | -109.35% | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -673.06% | -167.29% | -30.40% | — | — | — | — | — | — | — | — | — |
| Current Ratio | 4.91 | 11.11 | — | — | 12.92 | 7.71 | 8.51 | 11.09 | 3.59 | 0.36 | 10.11 | 10.34 |
| Quick Ratio | 4.91 | 11.11 | — | — | 12.92 | 7.71 | 8.51 | 11.09 | 3.59 | 0.36 | 10.11 | 10.34 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -147.98% | -41.56% | -29.44% | -77.12% | -69.02% | -57.17% | -58.60% | -117.67% | -6.43% | -196.38% | -40.87% | -37.61% |
| ROA | -117.87% | -37.81% | -21.78% | -68.88% | -63.68% | -51.16% | -48.94% | -100.92% | -5.22% | -103.16% | -33.73% | -33.55% |
| Asset Turnover | 0.18 | 0.23 | 0.72 | 0.00 | — | — | — | — | — | — | — | — |
| Book Value / Share | 2.02 | 4.86 | 2.77 | 39.02 | — | — | — | 4.81 | 1.66 | 0.90 | 0.88 | 2.67 |
CervoMed Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. With a commitment to improving patient outcomes, the company engages in the research and development of innovative therapies that target underlying neurological conditions such as Alzheimer's disease and Parkinson's disease. CervoMed Inc. is recognized for its scientific expertise in neurotherapeutics, exploring promising pathways that could lead to breakthrough solutions. Operating within the highly specialized biotech sector, the company contributes to expanding our understanding of neurobiology and developing targeted interventions. By collaborating with academic institutions, healthcare providers, and industry partners, CervoMed Inc. plays a critical role in advancing medical research and offering hope for patients suffering from debilitating neurological disorders.